Dr Lal PathLabs Q1 PAT up 27%, declares INR 5 interim dividend

Pat Growth 25pctExceptional ItemResults RestatedResults View source PDF Explain this filing

LALPATHLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹1690.10

prior close

₹1692.10

announcement price

In-mkt

timing

Nifty Smallcap 250market-0.3%+5.0% vs market

Healthcare Service Provider peers, median of 23sector-0.1%+4.8% vs sector

On the reaction day the stock moved 5.0 pts more than Nifty Smallcap 250 and 4.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.0

15m

+0.1

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7-0.3+5.0-0.1+4.8

Next day

+7.7+1.0+6.7+0.3+7.4

+6.8+0.5+6.3+0.2+6.6

+11.2+1.9+9.3+0.7+10.5

+10.6+1.1+9.5-0.8+11.4

+12.4+1.5+10.9-0.2+12.6

+11.7+3.1+8.6+1.8+9.8

15d

+13.0+3.6+9.5-1.8+14.8

+12.3+4.1+8.2-0.9+13.2

+15.8+2.9+12.9-0.3+16.1

+9.8-6.1+15.9-11.1+20.9

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr Lal PathLabs Q1 FY27 consolidated revenue rose 19% YoY to INR 7,977 million; PAT grew 27% to INR 1,705 million. Board declared INR 5 per share interim dividend, record date July 30. Also approved 80% stake acquisition in Ghana's Sunshine Healthcare (up to INR 380 million) and 30% in Neuome Technologies (up to INR 35 million). Granted 119,300 stock options.

Likely market impact

Strong Q1 with double-digit revenue and 27% PAT growth plus dividend and international expansion. Positive for shareholders.